

Balaram Gupta filed on May 18, 2006 and is hereby incorporated herein. Since Achard et al. '613 is no longer a citable reference, Durif et al. '917 in of itself only teaches the use of levadopa as a treatment for Parkinsons and there is no suggestion of the combination with azetidine derivatives. Therefore it is respectfully requested that the rejection of claims 1-2, 10, 20-21, 39, and 35 be

withdrawn and said application be allowed to pass onto allowance and issue

Respectfully submitted,



Craig M. Bell, Reg. No. 31,812
Attorney/Agent for Applicant

sanofi-aventis Inc. LLC
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2387
Telefax (908) 231-2626

sanofi-aventis Docket No. ST01023 US CNT